Astellas Pharma, XenoPort Conclude Licensing Agreement for XP13512 Analgesic Agent.Tokyo, Japan, Dec 1, 2005 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Astellas Pharma and XenoPort jointly announced on December 1 enterance into a licensing agreement on XP13512, an analgesic analgesic (ăn'əljē`zĭk), any of a diverse group of drugs used to relieve pain. Analgesic drugs include the nonsteroidal anti-inflammatory drugs (NSAIDs) such as the salicylates, narcotic drugs such as morphine, and synthetic drugs agent discovered and developed by XenoPort. XP13512 is a new chemical entity that is a Transported Prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. of gabapentin, an agent indicated for the treatment of seizure and neuropathic pain. Under the agreement terms, Astellas obtains the exclusive rights to develop and commercialize the agent in Japan, Korea, the Phlippines, Indonesia, Thailand and Taiwan. Accordingly, Astellas will receive an upfront payment of $85 million as well as milestone and royalty payments. Astellas plans to start a phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I targeting central neurological diseases and diabetes in mid 2006. Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion